The other patient was a 72-year-old woman, ASA III, with obesity (class II) and GERD, taking semaglutide (0.5 mg weekly, started 3 months ago) for obesity and had no symptoms on initiation of GLP-1 RA. Here, GLP1R is linked to obesity disorder.